CRISPR pioneer helps create gene-editing delivery systemnews2021-08-24T13:17:04+00:00August 24th, 2021|Fierce Pharma|
Novartis’ Kymriah flops in earlier lymphoma use, where Gilead, Bristol Myers CAR-T rivals succeedednews2021-08-24T11:32:37+00:00August 24th, 2021|Fierce Pharma|
FDA shares advice on bioequivalence studies for different dosage formsnews2021-08-24T10:34:56+00:00August 24th, 2021|Fierce Pharma|
Xeris, a rival to Lilly and Novo, gets FDA nod for glucagon kit news2021-08-24T10:31:35+00:00August 24th, 2021|Fierce Pharma|
Magnetic pills deliver insulin to refill implanted reservoirnews2021-08-24T10:27:42+00:00August 24th, 2021|Fierce Pharma|
Biohaven points up Nurtec dual-migraine approval with growing stable of celebrity usersnews2021-08-24T00:59:30+00:00August 24th, 2021|Fierce Pharma|
FDA hands Cara, Vifor a consolation prize with Korsuva nod in pruritis for chronic kidney disease patientsnews2021-08-23T22:47:48+00:00August 23rd, 2021|Fierce Pharma|
FDA hands Cara, Vifor a consolation prize with Korsuva nod in pruritus for chronic kidney disease patientsnews2021-08-23T22:47:48+00:00August 23rd, 2021|Fierce Pharma|
Lonza invests yet again, this time with a fill-finish line at new manufacturing site in Guangzhou, Chinanews2021-08-23T17:32:21+00:00August 23rd, 2021|Fierce Pharma|
Bristol Myers Squibb nabs priority review tag for $3.15B arthritis drug Orencia to prevent transplant rejectionnews2021-08-23T15:23:01+00:00August 23rd, 2021|Fierce Pharma|
